Management of maternal red cell alloimmunization has been revolutionized over the last 60 years. Advances in the prevention, screening, diagnosis, and treatment of alloimmune‐induced fetal anemia make this condition an exemplar for contemporary practice in fetal therapy. Since survival is now an expectation, attention has turned to optimization of long‐term outcomes following an alloimmunized pregnancy. In this review, the current management of red cell alloimmunization is described. Current research and future directions are discussed with particular emphasis on later life outcomes after alloimmune fetal anemia.

中文翻译：

---

红细胞同种免疫：2020 年更新。

在过去的 60 年中，母体红细胞同种免疫的管理发生了革命性的变化。同种免疫性胎儿贫血的预防、筛查、诊断和治疗方面的进展使这种情况成为当代胎儿治疗实践的典范。由于生存现在是一种期望，注意力已经转向优化同种免疫妊娠后的长期结果。在这篇综述中，描述了红细胞同种免疫的当前管理。讨论了当前的研究和未来的方向，特别强调同种免疫胎儿贫血后的晚年生活结果。